Antibody drug conjugates (ADCs) are formed by attaching drug substances to antibodies using a special linker moiety. The ideal ADC will specifically target antigen-expressing cells and release the drug in active form inside the cell. ADCs combine the specificity of monoclonal antibodies with high potency of cytotoxic drugs, leading to highly improved therapeutic efficacy and less side effects. However, the current challenges in ADC technology are related to creating highly homogeneous ADC products with high drug-to-antibody ratio as well as applying the technology to various drug substances.
Glykos focuses on discovery and development of products and technologies which are based on bioactive glycans. The company’s ADC technology includes novel linker technology and cytotoxic drug derivatives which overcome several limitations of current ADC applications. The key benefits of Glykos’ technology include flexible optimization of the hydrophilic character of the drug component using the company’s linkers and the ability to site-specifically conjugate practically any monoclonal antibody with the client?s toxin of choice.
Other benefits include homogeneous drug-to-antibody ratio (DAR) and significantly improved payload efficacy particularly against drug-resistant cells and low-abundance target antigens.
Glykos’ linkers can be used with practically any monoclonal antibody and with a large selection of potent toxins making our technology highly flexible as it can be integrated into clients existing development programs.
Viikinkaari 6
00790 Helsinki
Finland
Web: Glykos Finland Ltd
